Trial record 2 of 27 for:    bone health, calcium, osteoporosis | Child

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Berdine Martin, Purdue University
ClinicalTrials.gov Identifier:
NCT00244907
First received: October 25, 2005
Last updated: February 7, 2014
Last verified: February 2014
  Purpose

Estrogen is a hormone that helps prevent calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. Isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. This study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.


Condition Intervention Phase
Osteoporosis
Osteopenia
Dietary Supplement: Genistein vs Risedronate
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Metabolism and Bone Health

Resource links provided by NLM:


Further study details as provided by Purdue University:

Primary Outcome Measures:
  • Urinary markers of bone resorption; measured at the end of each treatment phase [ Time Frame: Every 50 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Serum markers of bone resorption and calcium absorption; measured at the end of each treatment phase [ Time Frame: Every 50 days ] [ Designated as safety issue: No ]

Enrollment: 23
Study Start Date: January 2006
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Genistein vs. Risedronate
Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
Dietary Supplement: Genistein vs Risedronate
Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
Other Name: Actonel
Active Comparator: Genistein dose and source
Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
Dietary Supplement: Genistein vs Risedronate
Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
Other Name: Actonel

Detailed Description:

Estrogen is a hormone that activates bone-forming cells and prevents calcium loss and bone breakdown. During menopause, estrogen levels decrease. Insufficient amounts of estrogen may accelerate bone breakdown and inhibit the body's ability to create new bone, thereby leading to bone loss and possibly osteoporosis. Various treatments have been developed to decrease bone loss in post-menopausal women. Actonel, for example, is an FDA-approved drug used to help prevent bone loss.

Phytoestrogens are plant compounds with a structure similar to estrogen. They have also been shown to help reduce the negative effects of menopause. Isoflavones are a particular type of phytoestrogens that are found in soy plants and may act like estrogen in providing possible protection against bone loss. This study will compare the effects of isoflavones (including genistein, a type of isoflavone) versus Actonel on calcium absorption and bone loss in post-menopausal women.

Participants in this double-blind cross-over study will first complete a screening process, which will include answering questions about their health habits, medical history, physical activity, and food patterns. They will then eat one soy bar daily for 3 days. On Day 4, a urine sample will be taken to assess their ability to metabolize phytoestrogen from soybeans. Participants will be randomly assigned to a specific treatment order. Participants will receive 1-4 unique soy isoflavones, followed by Actonel. Treatment phases will be separated by a 50-day washout period. All participants will also take calcium and vitamin D supplements throughout the study. Assessments will include bone density measurements, calcium absorption tests, and blood and urine tests. The study will last approximately 2.5 years.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • At least 4 years post-menopausal

Exclusion Criteria:

  • Not currently taking estrogen replacement therapy or undergoing any treatment for osteoporosis
  • Diagnosis of breast cancer
  • Results of mammogram suggesting breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00244907

Locations
United States, Indiana
Purdue University
West Lafayette, Indiana, United States, 47907
Sponsors and Collaborators
Purdue University
Investigators
Principal Investigator: Connie M. Weaver, PhD Purdue University
  More Information

Additional Information:
Publications:
Responsible Party: Berdine Martin, Research Scientist, Nutrition Science, Purdue University
ClinicalTrials.gov Identifier: NCT00244907     History of Changes
Other Study ID Numbers: P50 AT000477-06, P50AT000477-06
Study First Received: October 25, 2005
Last Updated: February 7, 2014
Health Authority: United States: Federal Government

Keywords provided by Purdue University:
Bone Resorption
Phytoestrogens
Calcium
Genistein
Equol

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Calcium Channel Blockers
Bone Density Conservation Agents
Musculoskeletal Diseases
Risedronic acid
Genistein
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Physiological Effects of Drugs
Anticarcinogenic Agents
Protective Agents
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Phytoestrogens
Estrogens, Non-Steroidal
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on September 22, 2014